Validation of Serum Neurofilament Light Chain as a Biomarker of Parkinson's Disease Progression.
Brit MollenhauerMohammed DaknaNiels KruseDouglas GalaskoTatiana ForoudHenrik ZetterbergSebastian SchadeRoland G GeraWenting WangFeng GaoMark FrasierLana M ChahineChristopher S CoffeyAndrew B SingletonTanya SimuniDaniel WeintraubJohn SeibylArthur W TogaCaroline M TannerKarl KieburtzKenneth MarekAndrew SiderowfJesse M CedarbaumSamantha J HuttenClaudia TrenkwalderDanielle GrahamPublished in: Movement disorders : official journal of the Movement Disorder Society (2020)
Neurofilament light chain in serum samples is increased in Parkinson's disease patients versus healthy controls, increases over time and with age, and correlates with clinical measures of Parkinson's disease severity. Although the specificity of neurofilament light chain for Parkinson's disease is low, it is the first blood-based biomarker candidate that could support disease stratification of Parkinson's disease versus other cognate/neurodegenerative disorders, track clinical progression, and possibly assess responsiveness to neuroprotective treatments. However, use of neurofilament light chain as a biomarker of response to neuroprotective interventions remains to be assessed. © 2020 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.